

52 / 129

Fig. 52

	Diversity	Equivalence	Prognosis Total (+) Vs (-)	Prognosis Total (homo)	Prognosis Total	Prognosis Total (+) vs (-)	Prognosis Total (homo)	Prognosis Stomach	Prognosis Total (+) vs (-)	Prognosis Total (homo)
DR	Diversity		Total	Total		Stomach	Stomach		Other cancers	Other cancers
5	arp_25	KR	K=R	K(-)>hetero, Rhomo>hetero	RR78.8			RR71.4		
6	arp_24	FL	F=L		FI66.7	F(-)>(+)		LI60.9		
13	arp_17	AT	A=T	Ahomo>hetero, T(-) >hetero	AA76.6			AA67.8		
14	arp_16	AV	A=V	A(-)>hetero, Vhomo>hetero	VV78.8			VV71.4		
29	arp_1	AS	A=S		SS83.36			SS100	A(+)>(-) S(-) >(+)	A Shomohetero> (-)
33	arp4	OR	O=R		OR68.3			RR68.1		
38	arp9	EKW	9K=11D=26Y=28H=30G		KW74.2			KW75.8		
39	arp10	EOY	10E=31V=38A=40Y= (1660)=(166R)		EY83.3			EY75		
40	arp11	DGLPSV	11G=13Y=14E=14=K25 Q=25R=30L, 11S=12K=12T, 11P=13R	V(-)>hetero	GV100, LL100Q		Vhetero>(-)	LL100		Phetero>homo
41	arp12	KT			KK66.5			TT70.7		
42	arp13	FGHRSY	13F=31F=31I		HY100, FR71.6			SY100, GR75.4	F(+)>(-)	Fhetero>(-), Rhetero>homo Shetero, (-) >homo
43	arp14	EK	E=K		EE66.2		Chetero> homo	EK80		
45	arp16	HOY			HQ71.50			HQ830		
55	arp25	OR	Q=R		LY70.2		Lhetero> homo	LY80.3		Fhetero>homo
57	arp28	DEH	28H=30G		DE69.2			DE69.4		
59	arp30	CDHLRY	30H=37L=38L=85A=85V		CC1000			CC1000		
60	arp31	FIV	31V=38A=40F=40Y, 31 (F=I)		FV77.8			FV76.2	I(+)>(-)	Fhetero>homo Ihetero>(-)

(Cut-off data added as was present in Figure as originally filed)

53 / 129

Fig. 53

			Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis
	Diversity	Equivalence	Total (+) vs (-)	Total (homo)	Total	Total (+) vs (-)	Total (homo)	Stomach	Stomach	Other (-) cancers
DR	Diversity		Total	Total				Stomach		
61	arp32	HY			HY66.9			YY68		
62	arp33	HN			NN66.7			HH71.4		
66	arp37	FLNSY			LL800			FS73.4		
67	arp38	ALV			LL800			AV78.8		
69	arp40	FY			FY73.1			FY71.6		
76	arp47	FY			FY67.4			YY68.9		
86	arp57	ADSV			AV73.70			AD72.5, SV72.5		
87	arp58	AE			AE67			AE71.1		
89	arp60	HAY			HS73.7			HY68.4		
96	arp67	FIL			FI68.5			FI72.2		
99	arp70	DOR			DD69.4			DD72.7		
100	arp71	AEKR			AR63.5, ER67.2, AE72.6			EK750		
					AA66.3			AA68.1		
	arp73	AG			73A=73G=74R=74N= 77N=77T					
103	arp74	AEIQR			LR80			AQ100.0		
106	arp77	NT			TT66.4			TT68.2		
107	arp78	VY			VY67.1			VY68.6		

(Cut-off data added as was present in Figure as originally filed)

54 / 129

Fig. 54

	Diversity	Equivalence	Prognosis		Prognosis		Prognosis		Prognosis		Prognosis		Prognosis		Prognosis	
			Total (+) Vs (-)	Total	Total (homo)	Total	Total (+) vs (-)	Total (homo)	Stomach	Stomach	Stomach	Stomach	Total (+) vs (-)	Other cancers	Total (homo)	Other cancers
DR	Diversity															
114	arp85	AV	A=V			AA80					VV68.1					
115	arp86	GV	G=V			GG68.5					VV69.4					
125	arp96	EHQY				EE100					EE100					Q(-) hetero-homo
127	arp98	EK	98E=98K=104A=142V			EK68.5					EK72.1					
133	arp104	AS	A=S			AS70.5					AS72.1					
149	arp120	NS	S=N			NN77.9					NN72.9					
					N- hetero Shomo>h etero											
162	arp133	LR	133L=133R=142M=142V			RR67.5					LL69.7		R(+)>(-)			
169	arp140	AT				TT71.5					TT74.1					
171	arp142	MV	M=V			VV67.5					MM69.7		V(+)>(-)			
178	arp149	HQY	H=Q			HH68.1					HH70.8					
	arp164	FV														
195	arp166	OR	O=R			RR67					QR68.6					
209	arp180	LV	L=V			LL75.1					RR68.6					
210	arp181	MT				TT67.3					LL70.1					
218	arp189	RS	R=S			SS100					TT69					
260	arp231	PO	P=Q			QQ66.7					SS100					
262	arp233	RT	R=T			TT67.4					QQ67.9					
									T(-)>(+)	R Thomo>h etero(-)	RR78.2				R Thetero(-) -thomo	
	All survived					DR11GLGV LL(5)					DR30CLC C(4)					

(Cut-off data added as was present in Figure as originally filed)

Fig. 55

			Prognosis	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect
	Diversit	Equivalence	Other cancers	Total (+) vs (-)	Total (homo)	All cases	Total (+) vs (-)	Total (homo)	Stomach cancer
DR	Diversit			Total	Total		Stomach	Stomach	
arp_25	Y	K=R	RR100						
arp_24	FL	F=L	FL100						
arp_17	AT	A=T	AA100			Immunotherapy AA 71.4			
arp16	AV	A=V	VV100						
arp1	AS	A=S	AA90.90						
arp4	OR	O=R	QQ69.3						
arp9	EKW	9K=11D=26V=28 H=30G	KW71.2			Immunotherapy KW (86.7)		Immunotherapy E (-), (homo)>hetero	Immunotherapy KW 84.6
arp10	EQY	10E=31V=38A=4 0Y=(166Q)=(166 R)	EY100	Immunotherapy E(-)>(+)	Immunotherapy E(-) >hetero		Immunotherap y E(-)>(+)	Immunotherapy E(-) >hetero	
arp11	DGLPS V	11G=13V=14E=1 4=K25Q=25R=3 0L. 11S=12K=12T. 11P=13R	LL1000		Immunotherapy V(homo,((-))>hetero	no adjuvant therapy DS(83.4)DV(79.6), Immunotherapy DP (84.6)		Immunotherapy V(homo,((-))>hetero	
arp12	KT		KK64.2						
arp13	FGHRS Y	13F=13F=31I	FR74.20	Immunotherapy Shetero>(-)>homo		no adjuvant therapy GH(89.9), Immunotherapy FS(81.9)		Immunotherapy Hhomo,((-))>hetero	
arp14	EK	E=K	EE63.5						
arp16	HQY		QY100						
arp25	OR	O=R							
arp26	FLY		LL100	Chemotherapy 26L(+)>(-)	Chemotherapy Lhetero>(-)>homo, Immunotherapy Lhetero,((-)>homo	no adjuvant therapy FL(87), Immunotherapy FL(61.4)		Chemotherapy Lhetero,((-))>homo, Immunotherapy Lhetero,((-)>homo	Immunotherapy LY66.7
arp28	DEH	28H=30G	EE63.3					Immunotherapy Ehetero,((-)>homo	Immunotherapy EH (68.6)
arp30	CGHLR Y	30H=37L=38L=8 5A=85V	CC100	no adjuvant therapy H(+)>(-) Immunotherapy R(-)>(+)	Immunotherapy R(-) >hetero		Immunotherap y R(-)>(+)		
arp31	FIV	31V=38A=40F=4 0Y, 31(F=I)	FV80	Immunotherapy V(-)>(+)	Immunotherapy V(-) >hetero	Immunotherapy FF (55.5) FI(60.7)	Immunotherap y V(-)>(+)	Immunotherapy V(-) >hetero	

(Cut-off data added as was present in Figure as originally filed)

Fig. 56

			Prognosis	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect
	Diversity	Equivalence	Other cancers	Total (+) vs (-)	Total (homo)	All cases	Total (+) vs (-)	Total (homo)	Stomach cancer
DR	Diversity			Total	Total		Stomach	Stomach	
arp32	HY	H=Y	HY64.8				Immunotherapy N(-)>(+)	Immunotherapy H(homo)>(-) (-) hetero, Immunotherapy N(-)> homo, hetero	Immunotherapy HH(87.5)
arp33	HN	H=N	HN64.5						
arp37	FLNSY	F=S	FL83.30	Chemotherapy F(-)>(+), no adjuvant therapy L (+)>(-), Immunotherapy N(+)>(-)	Chemotherapy F(-) >hetero, homo, Immunotherapy N(hetero) (>homo)>(-)	Chemotherapy LY(70.9), Immunotherapy NS(72.5)			Immunotherapy NS(69.1)
arp38	ALV		LL 100	Immunotherapy A(-)>(+), no adjuvant therapy L(+)>(-)	Immunotherapy A(-) >hetero		Immunotherapy A(-)>(+)	Immunotherapy A(-) >hetero	
arp40	FY	F=Y	FY75	Immunotherapy Y(-)>(+)	Immunotherapy Fromo>hetero, Immunotherapy Y(-) >hetero	Immunotherapy FF(57.5)		Immunotherapy Y (-) >hetero	
arp47	FY	F=Y	FY67.3						Chemotherapy FF(74.5)
arp57	ADSV		AV88.90	Chemotherapy A(-)>(+)	no adjuvant therapy Shetero (-)>homo	no adjuvant therapy SV(92.2), Chemotherapy DD(60.3), Immunotherapy AD(76.2)			no adjuvant therapy SV(100), Immunotherapy AD(83.3)
arp58	AE	A=E	AA63.5	Chemotherapy H(-)>(+)		Chemotherapy YY (56.8)			
arp60	HAY		HS88.9	Immunotherapy I(-)>(+)					Chemotherapy II(74.8)
arp67	FIL		FF72.4	Chemotherapy L(-)>(+)	Immunotherapy I(-) >homo, hetero, no adjuvant therapy L(hetero)>(-), homo, Chemotherapy L(-) >hetero, homo	no adjuvant therapy IL(82.8), Chemotherapy FI(63.4), Immunotherapy FI(68)		Chemotherapy I(homo>hetero, (-), Chemotherapy LI(-) homo>hetero	
arp70	DOR		RR69.4	Chemotherapy R(-)>(+)				no adjuvant therapy Dhetero>homo, (-)	no adjuvant therapy DQ (86.5)
arp71	AEKR		KR78.80	no adjuvant therapy K(-) >(+)	no adjuvant therapy A(hetero, (-)>homo, E(hetero, I(-)>homo	no adjuvant therapy RR(81.8), Immunotherapy ER(73.7)	no adjuvant therapy K(-)>(+)		no adjuvant therapy ER(91.7), Chemotherapy AA(77.8)
arp73	AG	73A=73G=74 R=74N=77N=77T	AG65.6				Chemotherapy G(-)>(+)	Chemotherapy Ahomo>hetero, Chemotherapy G(-)>hetero	Chemotherapy AA (59)
arp74	AELQR	R=N	ER100	Chemotherapy E(-)>(+), Immunotherapy E(+)>(-)	Immunotherapy A(hetero, I(-)>homo, Immunotherapy E(hetero, homo)>(-)	Immunotherapy AE(67.9)	Chemotherapy R(-)>(+)	Immunotherapy A(hetero) (-) homo, Chemotherapy (-) >hetero	no adjuvant therapy EL(90.9), Chemotherapy AI (66.1), Immunotherapy AE(67.5)
arp77	NI	N=I	NI83.3				Chemotherapy N(-)>(+)	Chemotherapy NI(-) >hetero, Chemotherapy Thomo>hetero	Chemotherapy TI(56)
arp78	VY	V=Y	VV69.3						

(Cut-off data added as was present in Figure as originally filed)

58 / 129

Fig. 58

			Treatment Effect	Treatment Effect	DR	DR	DR	DR
	Diversity	Equivalence	Treatment Effect Total (+) vs (-)	Treatment Effect Total (homo)	Other cancers	Cancer in Family	Metastases	Total (ratio of advanced cancer)
DR	Diversity		Other cancers	Other cancers				
ap_25	KR	K=R						
ap_24	FL	F=L				FLB0LL22.90		
ap_17	AT	A=T						
ap_16	AV	A=V						
ap_1	AS	A=S			no adjuvant therapy AA(100)			AS73.3 AA44.40
ap4	QR	Q=R						
ap9	EKW	9K=11D=26Y =28H=30G	no adjuvant therapy Whetero (-) >homo	no adjuvant therapy Whetero (-)				
ap10	EOY	10E=31V=38A =40Y=(1660) =(166R)						
ap11	DGLPSV	11G=13Y=14 E=14=K25Q= 25R=30L 11S=12K=12T 11P=13R	no adjuvant therapy Phetero (-) >homo					
ap12	KT							
ap13	FGHRSY	13F=31F=31I	no adjuvant therapy Rhetero (-) >1homo Chemotherapy Shetero (-)>1homo Immunotherapy Shetero (-)>1homo	no adjuvant therapy FR(90) Chemotherapy FR(72) Immunotherapy FS(100)			FT22.6, FF0, GR0, O	
ap14	EK	E=K				#		
ap16	HQY						QQ100, YY6, 30	
ap25	QR	Q=R						
ap26	FLY		Chemotherapy F(-) (hetero)>homo Chemotherapy hetero (-)>homo			#		
ap28	DEH	28H=30G		Chemotherapy EE100		#		
ap30	CDHLRY	30H=37L=38L =85A=85V 31V=38A=40F =40Y.31(F=I)						
ap31	FIV							

(Cut-off data added as was present in Figure as originally filed)

59 / 129

Fig. 59

	Diversity	Equivalence	Treatment Effect Total (+) vs (-)	Treatment Effect Total (homo)	Treatment Effect Other cancers	DR Cancer in Family	DR Metastases	DR Total (ratio of advanced cancer)	DR Smoking
DR	Diversity		Other cancers	Other cancers					
ap32	HY	H=Y	Chemotherapy Y(+)>(-) Immunotherapy Y(+)>(-) Chemotherapy H(-)>(+)	Chemotherapy H(-))hetero>homo, Immunotherapy hetero (-)homo Chemotherapy Yhetero homo>(-) Immunotherapy Yhetero homo>(-)	Chemotherapy HY(55.6) Immunotherapy HY(55.6)				
ap33	HN	H=N						HN18.3 NN9.80	
ap37	FLNSY	F=S		Chemotherapy F(-))hetero>homo, no adjuvant therapy Shetero (-)homo	no adjuvant therapy YY(61.3) Chemotherapy FS(100) Immunotherapy NS(80)	#			
ap38	ALV								
ap40	FY	F=Y							
ap47	FY	F=Y							
ap57	ADSV		Chemotherapy A(-)>(+)	Chemotherapy A(-)> (hetero) homo, Immunotherapy Shetero (-)homo	no adjuvant therapy SV(61.9) Chemotherapy VY(65.7) Immunotherapy DS(76.9)				
ap58	AE	A=E							
ap60	HAY			Chemotherapy H(-))hetero) homo	Chemotherapy SS(65.7) Immunotherapy HT(75) no adjuvant therapy FF(65.7) IL(6.3)				
ap67	FIL								
ap70	DOR								
ap71	AEKR			no adjuvant therapy Ahetero (-)>homo	no adjuvant therapy AR(74.9)				
ap73	AG	73A=73G=74 R=74N=77N=77T							
ap74	AELOP	R=N	no adjuvant therapy L(-)>(+)	no adjuvant therapy Ahetero (-)>homo	no adjuvant therapy(AE81) Chemotherapy (AE54.4)				
ap77	NT	N=T							
ap78	VY	V=Y							

(Cut-off data added as was present in Figure as originally filed)

60 / 129

Fig. 60

	Diversity	Equivalence	Treatment Effect Total (+) vs (-)	Treatment Effect Total (homo)	Treatment Effect Other cancers	DR Cancer in Family	DR Metastases	DR Total (ratio of advanced cancer)	DR Smoking
DR	Diversity		Other cancers	Other cancers					
ap85	AV	A=V	Chemotherapy G(+)>(-)	Chemotherapy Ghomo hetero>(-)	Chemotherapy W(80)	AV38 T A400	#		
ap86	GV	G=V		no adjuvant therapy Q(-)	no adjuvant therapy HY(100)			#	
ap96	EHQY)hetero>homo (immunotherapy Ehetero (-)	immunotherapy EK(88.4)				
ap98	EK	98E=98K=104 A=104S	immunotherapy K(+)>(-))hetero>homo (immunotherapy Ehetero (-)	immunotherapy EK(88.4)				
ap104	AS	A=S	immunotherapy S(+)>(-)	Khetero homo>(-) (immunotherapy Ahetero (-)	immunotherapy AS(61.9)				
ap120	NS	S=N		Shetero homo>(-)		#		#	
ap133	LR	133L=133R=1 42M=142V	no adjuvant therapy R(+)>(-)	no adjuvant therapy Lhetero (-)>homo, no adjuvant therapy Rhomo hetero>(-)	no adjuvant therapy RR(69.1)				
ap140	AT								
ap142	MV	M=V	no adjuvant therapy V(+)>(-)	no adjuvant therapy Mhetero (-)>homo, no adjuvant therapy Vhomo hetero>(-)	no adjuvant therapy VV(69.1)				
ap146	HOY	H=O							
ap164	FV								
ap166	QR	Q=R							
ap180	LV	L=V			no adjuvant therapy LV(100)	#			#
ap181	MT								
ap189	RS	R=S							
ap231	PO	P=Q							
ap233	RT	R=T	immunotherapy T(+)>(-)	immunotherapy Rhetero (-)	immunotherapy RT(77.9)				
All	survived			hetero homo>(-)					

(Cut-off data added as was present in Figure as originally filed)

61 / 129

Fig. 61

		Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Treatment	Treatment	Treatment
		Equivalence	Total (+) vs (-)	Total (homo)	Total (+) vs (-)	Total (homo)	Total (+) vs (-)	Total (homo)	Total (+) vs (-)	Total (+) vs (-)	Total (+) vs (-)	Total (+) vs (-)
DP	Diversity		Total	Total	Stomach	Stomach	Stomach	Stomach	Other cancers	Other cancers	Other cancers	Total
37	app8 LV	8L=8V=9F =11G=11L		LV67.4		VV77.8				LV64.70		
38	app9 FHY			FY68.2		YY65.7				FY65.80		
40	app11 GL	G=L		GL67.3		LL77.8				GG64, GL64.70		
64	app35 FLY			FF68		FY76.90				LL66.8, LY68.8		
65	app36 AV	A=V		AA65.7		AA60				AA100		
84	app55 ADE			AA65.7		AA60				AA100		no adjuvant therapy AD(79)
85	app56 AE			EE67.5		EE70.8				AA67.3		
96	app57 DE			DD68.5		DD76				EE64.2		
94	app65 FIL	65I=65L		LL65.7		LL85.7				LL64.6		
98	app69 EK	E=K		EK68.6		EK69.4				EK67.80		no adjuvant therapy Ebelero(-) no adjuvant therapy EK(61.4)
105	app76 IMV			II100		IV100				IM67.70		
113	app84 DG			DG66.9		GG70.8				DG65.9		
114	app85 EG			EG66.9		GG70.8				EG65.9		
115	app88 AP			AP66.9		PP70.8				AP65.9		

(Cut-off data added as was present in Figure as originally filed)

62 / 128

(Cut-off data added as was present in Figure as originally filed)

63 / 129

Fig. 63

	Treatment Effect Total (+) vs (-)	Treatment Effect Total (homo)	Treatment Effect Stomach cancer	Treatment Effect Total (+) vs (-)	Treatment Effect Total (homo)	Treatment Effect Other cancers	DP Category/rate of malignancy	DP Metastases
DP Diversity	Stomach	Stomach		Other cancers	Other cancers			
app8 LV				no adjuvant therapy	no adjuvant therapy	no adjuvant therapy (LV)	VV95.2 LL89.80	
app9 FHY	Immunotherapy Y H(-)>P(+)	Immunotherapy H(-) (homo)>hetero	Immunotherapy FY(67.1) FF(65)	no adjuvant therapy FY(+)>P(-)	no adjuvant therapy Fhetero homo(-) no adjuvant therapy H(-) (hetero)>homo	no adjuvant therapy (FY)	#	
app11 GL				no adjuvant therapy GL(+)>P(-)	no adjuvant therapy Ghetero homo(-) no adjuvant therapy L(-) (hetero)>homo	no adjuvant therapy (GL)	VV95.2 LL89.80	
app35 FLV			Chemotherapy (FF)			Chemotherapy (LV)		#
app36 AV		Chemotherapy A(-) (homo)>hetero Chemotherapy Vhomo(-) >hetero	Chemotherapy (VV)					
app5 ADE		Chemotherapy A(-) (homo)>hetero						AE44.8 AA10
app56 AE				no adjuvant therapy A(+)>P(-)	no adjuvant therapy Ahetero(-) homo no adjuvant therapy Ehetero(-) (homo)	no adjuvant therapy DE(76.3)		
app57 DE				no adjuvant therapy E(+)>P(-)	no adjuvant therapy Dhetero(-) homo no adjuvant therapy Ehetero homo(-)	no adjuvant therapy DE (76.8)	VV95.3 LL89.60	
app65 FIL				no adjuvant therapy L(+)>P(-)	no adjuvant therapy Lhetero homo no adjuvant therapy Lhetero homo(-) no adjuvant therapy E(-) (hetero)>homo no adjuvant therapy Lhetero homo(-)	no adjuvant therapy LL(100)		
app69 EK	Immunotherapy Y E(-)>P(+)	no adjuvant therapy Ehetero(-) homo Immunotherapy E(-) (hetero)>homo no adjuvant therapy Khetero(homo)(-) Immunotherapy K(homo hetero)>(-)	no adjuvant therapy EK (85.4) Immunotherapy KK (58.3)	no adjuvant therapy K(+)>P(-)		no adjuvant therapy EK(71.7)		
app76 IMV		Chemotherapy L(-) (homo)>hetero	Chemotherapy MV(64)		no adjuvant therapy	no adjuvant therapy MV(79)	VV95.6 LL86.70	
app84 DG					no adjuvant therapy		DD92.1 GG87.80	
app85 EG							EE92.1 GG87.80	
app86 AP							VV92.1 MM87.60	

(Cut-off data added as was present in Figure as originally filed)